S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
NASDAQ:AMED

Amedisys (AMED) Stock Price, News & Analysis

$90.40
-0.38 (-0.42%)
(As of 04/19/2024 ET)
Today's Range
$90.34
$90.98
50-Day Range
$90.40
$94.50
52-Week Range
$73.10
$96.44
Volume
384,904 shs
Average Volume
226,431 shs
Market Capitalization
$2.95 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$97.50

Amedisys MarketRank™ Stock Analysis

Analyst Rating
Hold
2.13 Rating Score
Upside/​Downside
7.9% Upside
$97.50 Price Target
Short Interest
Healthy
7.82% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.61
Upright™ Environmental Score
News Sentiment
0.71mentions of Amedisys in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
9.47%
From $4.54 to $4.97 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.11 out of 5 stars

Medical Sector

324th out of 909 stocks

Home Health Care Services Industry

6th out of 8 stocks

AMED stock logo

About Amedisys Stock (NASDAQ:AMED)

Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients. The Hospice segment offers services that is designed to provide comfort and support for those who are dealing with a terminal illness, including cancer, heart disease, pulmonary disease, or Alzheimer's. The High Acuity Care offers essential elements of inpatient hospital, skilled nursing facility care, and palliative care to patients in their homes. Amedisys, Inc. was incorporated in 1982 and is headquartered in Baton Rouge, Louisiana.

AMED Stock Price History

AMED Stock News Headlines

“More countries ditch the US dollar”
Since March 2018, China started purchasing oil in gold-backed yuan. By December 2022, Foreign Minister Wang Yi stated that Chinese-Arab relations experienced a "historic improvement." after arab nations ditched the dollar to trade with China. On June 6, 2023 China told its banks to slash interest rates on US dollars.
Surescripts exploring a sale: report
“More countries ditch the US dollar”
Since March 2018, China started purchasing oil in gold-backed yuan. By December 2022, Foreign Minister Wang Yi stated that Chinese-Arab relations experienced a "historic improvement." after arab nations ditched the dollar to trade with China. On June 6, 2023 China told its banks to slash interest rates on US dollars.
CAH Mar 2024 103.000 put
Q4 2023 Blue Owl Capital Corp Earnings Call
Amedisys (AMED) Q4 Earnings Lag Estimates
Kain Capital-Backed PERA Holdings Hires CEO and CCO
AMED Mar 2024 95.000 put
AMED Mar 2024 70.000 put
AMED Feb 2024 90.000 call
See More Headlines
Receive AMED Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amedisys and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/21/2024
Today
4/21/2024
Next Earnings (Estimated)
5/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Home health care services
Sub-Industry
Health Care Services
Current Symbol
NASDAQ:AMED
CUSIP
02343610
Employees
19,000
Year Founded
1982

Price Target and Rating

Average Stock Price Target
$97.50
High Stock Price Target
$101.00
Low Stock Price Target
$81.00
Potential Upside/Downside
+7.9%
Consensus Rating
Hold
Rating Score (0-4)
2.13
Research Coverage
8 Analysts

Profitability

Net Income
$-9,750,000.00
Pretax Margin
1.77%

Debt

Sales & Book Value

Annual Sales
$2.24 billion
Cash Flow
$6.11 per share
Book Value
$34.31 per share

Miscellaneous

Free Float
32,080,000
Market Cap
$2.95 billion
Optionable
Optionable
Beta
0.86

Social Links

10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives


AMED Stock Analysis - Frequently Asked Questions

Should I buy or sell Amedisys stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Amedisys in the last year. There are currently 7 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" AMED shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AMED, but not buy additional shares or sell existing shares.
View AMED analyst ratings
or view top-rated stocks.

What is Amedisys' stock price target for 2024?

8 brokerages have issued twelve-month price objectives for Amedisys' stock. Their AMED share price targets range from $81.00 to $101.00. On average, they predict the company's stock price to reach $97.50 in the next twelve months. This suggests a possible upside of 7.9% from the stock's current price.
View analysts price targets for AMED
or view top-rated stocks among Wall Street analysts.

How have AMED shares performed in 2024?

Amedisys' stock was trading at $95.06 at the start of the year. Since then, AMED stock has decreased by 4.9% and is now trading at $90.40.
View the best growth stocks for 2024 here
.

Are investors shorting Amedisys?

Amedisys saw a drop in short interest in the month of March. As of March 31st, there was short interest totaling 2,490,000 shares, a drop of 20.2% from the March 15th total of 3,120,000 shares. Based on an average daily volume of 291,300 shares, the short-interest ratio is currently 8.5 days. Approximately 7.8% of the shares of the company are sold short.
View Amedisys' Short Interest
.

When is Amedisys' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our AMED earnings forecast
.

How were Amedisys' earnings last quarter?

Amedisys, Inc. (NASDAQ:AMED) announced its quarterly earnings data on Wednesday, February, 21st. The health services provider reported $0.94 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.04 by $0.10. The health services provider had revenue of $570.79 million for the quarter, compared to analyst estimates of $566.85 million. Amedisys had a positive trailing twelve-month return on equity of 12.76% and a negative net margin of 0.44%. The company's revenue for the quarter was up 1.6% on a year-over-year basis. During the same period in the prior year, the firm earned $1.16 earnings per share.

What is Paul B. Kusserow's approval rating as Amedisys' CEO?

478 employees have rated Amedisys Chief Executive Officer Paul B. Kusserow on Glassdoor.com. Paul B. Kusserow has an approval rating of 79% among the company's employees. 60.0% of employees surveyed would recommend working at Amedisys to a friend.

What other stocks do shareholders of Amedisys own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amedisys investors own include NVIDIA (NVDA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Pfizer (PFE), Adobe (ADBE), Intel (INTC), QUALCOMM (QCOM), Broadcom (AVGO), Cisco Systems (CSCO) and Home Depot (HD).

Who are Amedisys' major shareholders?

Amedisys' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Leeward Investments LLC MA (0.31%), Bridge City Capital LLC (0.09%) and Banque Cantonale Vaudoise (0.00%). Insiders that own company stock include Bruce D Perkins, Christopher Gerard, David L Kemmerly, Denise M Bohnert, Michael Paul North, Richard A Lechleiter and Scott G Ginn.
View institutional ownership trends
.

How do I buy shares of Amedisys?

Shares of AMED stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AMED) was last updated on 4/21/2024 by MarketBeat.com Staff

From Our Partners